Post-approval studies (Phase 4)Study completedNCT04505774What this trial is testingAccelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTEWho this might be right forCovid19 Matthew Neal MD 3,591
Not applicableUnknownNCT06251453What this trial is testingImpact of Sodium-glucose Cotransporter 2 Inhibitors on Post-operative Atrial Fibrillation in Cardiothoracic SurgeryWho this might be right forAtrial Fibrillation Hamad Medical Corporation 3,280
Testing effectiveness (Phase 2)Active Not RecruitingNCT07678203What this trial is testingDapagliflozin to Reduce the Decline in Renal Function in Patients Newly Diagnosed With Lupus NephritisWho this might be right forLupus Nephritis (LN)Chronic Kidney DiseaseSGLT 2 Inhibitors+1 more Hospital Civil Juan I. Menchaca 30
Post-approval studies (Phase 4)Looking for participantsNCT06291155What this trial is testingMechanism of SGLT2 Inhibition in the KidneyWho this might be right forType 2 DiabetesDiabetic Kidney Disease University of Michigan 20
Early research (Phase 1)Active Not RecruitingNCT02891954What this trial is testingGenetics of Response to CanagliflozinWho this might be right forDiabetes Mellitus, Type 2 University of Maryland, Baltimore 700
Not applicableStudy completedNCT07379788What this trial is testingARNI Combined With SGLT2 Inhibitors on Functional Mitral Regurgitation RemodelingWho this might be right forHeart Failure Rehab Werida 180
Testing effectiveness (Phase 2)Study completedNCT01248364What this trial is testingDetermine Acute (After First Dose) and Chronic (After 28 Days) Effects of Empagliflozin (BI 10773) on Pre and Postprandial Glucose Homeostasis in Patients With Impaired Glucose Tolerance and Type 2 Diabetes Mellitus and Healthy SubjectsWho this might be right forDiabetes Mellitus, Type 2 Boehringer Ingelheim 91
Not applicableStudy completedNCT03817463What this trial is testingObserve the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 DiabetesWho this might be right forDiabetes Mellitus, Type 2 Boehringer Ingelheim 327,624
Post-approval studies (Phase 4)Not Yet RecruitingNCT07766109What this trial is testingDiscontinuation or Continuation of SGLT-2 Inhibitors Before Cardiac SurgeryWho this might be right forHeart FailureCardiac Surgery University Hospital, Toulouse 434
Testing effectiveness (Phase 2)Looking for participantsNCT07174687What this trial is testingSGLT2 Inhibitors in Geographic AtrophyWho this might be right forRetinal DegenerationRetinal DiseasesEye Diseases+2 more Washington University School of Medicine 70
Testing effectiveness (Phase 2)Looking for participantsNCT06155604What this trial is testingSGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney DiseaseWho this might be right forLupus NephritisChronic Kidney Diseases The University of Hong Kong 150
Post-approval studies (Phase 4)Study completedNCT02175784What this trial is testingAssess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes MellitusWho this might be right forType 2 Diabetes Mellitus Astellas Pharma Inc 262
Post-approval studies (Phase 4)Looking for participantsNCT07631156What this trial is testingSTEPwise De-escalation and Optimizing Withdrawal of ARNI and SGLT2i in Normalized Heart FailureWho this might be right forHeart Failure With Reduced Ejection FractionHeart FailureVentricular Dysfunction, Left Kyungsub Song 80
Not applicableStudy completedNCT05344963What this trial is testingDeformation Imaging by Strain in Chronic Heart Failure Over Gliflozins: an Echocardiographic Register on Sodium-GLucose coTransporter-2 InhibitorsWho this might be right forSodium-GLucose coTransporter-2 InhibitorsHeart Failure With Reduced Ejection Fraction Matteo Cameli 503
Not applicableNot Yet RecruitingNCT06668753What this trial is testingEffect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic NephropathyWho this might be right forEffect of SGLT2 Inhibitors NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy Assiut University 114
Post-approval studies (Phase 4)Study completedNCT02914691What this trial is testingEffects of Dapagliflozin Treatment on Urinary Proteomic Patterns in Patients With Type 2 DiabetesWho this might be right forType 2 DiabetesDiabetic Nephropathy Peter Rossing 40
Post-approval studies (Phase 4)Looking for participantsNCT07614230What this trial is testingSGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in DiabetesWho this might be right forType 2 Diabetes Mellitus (T2DM)Coronary Artery DiseaseAtherosclerosis Junjie Yang 144
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07146880What this trial is testingEmpagliflozin as a Potential Therapeutic Solution for Patients With Brugada SyndromeWho this might be right forBrugada Syndrome (BrS) National Taiwan University Hospital 10
Post-approval studies (Phase 4)Active Not RecruitingNCT03878459What this trial is testingDapagliflozin Plus Pioglitazone in T1DMWho this might be right forType 1 Diabetes Mellitus The University of Texas Health Science Center at San Antonio 120
Not applicableStudy completedNCT06964607What this trial is testingImpact of Sodium Glucose Co-transporter 2-Inhibitors on Clinical Outcome and Left Ventricular Function in Patients Presented by Acute Myocardial InfarctionWho this might be right forSodium-glucose Cotransporter 2InhibitorsClinical Outcome+2 more Tanta University 80